Anticorps Polyclonal de lapin anti-RAB2

• Phare
• Validé par KD/KO

RAB2 Polyclonal Antibody for WB, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IF, IHC, ELISA

Conjugaison

Non conjugué

Publications

12

N° de cat : 15420-1-AP

Synonymes

RAB2, RAB2A, Ras related protein Rab 2A

---

Galerie de données de validation

• 

  WB analysis of mouse brain using 15420-1-AP

  mouse brain tissue were subjected to SDS PAGE followed by western blot with 15420-1-AP (RAB2 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of rat brain using 15420-1-AP

  rat brain tissue were subjected to SDS PAGE followed by western blot with 15420-1-AP (RAB2 antibody at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 15420-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 15420-1-AP (RAB2 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HeLa using 15420-1-AP

  HeLa cells were subjected to SDS PAGE followed by western blot with 15420-1-AP (RAB2 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HEK-293 using 15420-1-AP

  HEK-293 cells were subjected to SDS PAGE followed by western blot with 15420-1-AP (RAB2 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of mouse lung using 15420-1-AP

  mouse lung tissue were subjected to SDS PAGE followed by western blot with 15420-1-AP (RAB2 antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human brain using 15420-1-AP

  Immunohistochemical analysis of paraffin-embedded human brain using 15420-1-AP (RAB2 antibody) at dilution of 1:100 (under 10x lens).

• 

  IHC staining of human brain using 15420-1-AP

  Immunohistochemical analysis of paraffin-embedded human brain using 15420-1-AP (RAB2 antibody) at dilution of 1:100 (under 40x lens).

• 

  IHC staining of human breast cancer using 15420-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 15420-1-AP (RAB2 antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 15420-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 15420-1-AP (RAB2 antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human breast cancer using 15420-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 15420-1-AP (RAB2 antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human breast cancer using 15420-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer using 15420-1-AP (RAB2 antibody) at dilution of 1:50 (under 40x lens).

---

Applications testées

• Résultats positifs en WB: tissu cérébral de souris, cellules HEK-293, cellules HeLa, tissu cérébral de rat, tissu pulmonaire de souris
• Résultats positifs en IHC: tissu cérébral humain, tissu de cancer du sein humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:1000-1:4000
• Immunohistochimie (IHC): IHC : 1:20-1:200

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 4 publications below
• WB: See 10 publications below
• IF: See 2 publications below

Informations sur le produit

15420-1-AP cible RAB2 dans les applications de WB, IF, IHC, ELISA et montre une réactivité avec des échantillons Humain, rat, souris

• Réactivité: Humain, rat, souris
• Réactivité citée: Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: RAB2 Protéine recombinante Ag7708
• Nom complet: RAB2A, member RAS oncogene family
• Masse moléculaire calculée: 24 kDa
• Poids moléculaire observé: 24 kDa
• Numéro d’acquisition GenBank: BC008929
• Symbole du gène: RAB2A
• Identification du gène (NCBI): 5862
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

The protein belongs to the Rab family, members of which are small molecular weight guanosine triphosphatases (GTPases) that contain highly conserved domains involved in GTP binding and hydrolysis. The Rabs are membrane-bound proteins, involved in vesicular fusion and trafficking. This protein is a resident of pre-Golgi intermediates, and is required for protein transport from the endoplasmic reticulum (ER) to the Golgi complex. This antibody can recognize both RAB2A and RAB2B.

Publications

Species	Application	Title
human	WB	Nat Commun; C9orf72-catalyzed GTP loading of Rab39A enables HOPS-mediated membrane tethering and fusion in mammalian autophagy; Authors - Shen Zhang
human	WB	Cell Host Microbe; A Brucella Type IV Effector Targets the COG Tethering Complex to Remodel Host Secretory Traffic and Promote Intracellular Replication.; Authors - Cheryl N Miller ; KD Validated
human	WB	Nat Commun; Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells.; Authors - Shingo Kozono
		Proc Natl Acad Sci U S A; Disruption of the AMPK-TBC1D1 nexus increases lipogenic gene expression and causes obesity in mice via promoting IGF1 secretion.; Authors - Liang Chen
human	WB	Cell Rep; Consecutive functions of small GTPases guide HOPS-mediated tethering of late endosomes and lysosomes; Authors - Ariane Schleinitz
		EMBO Rep; RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs.; Authors - Hiroaki Kajiho